Search This Blog

Thursday, July 30, 2026

Karyopharm misses endpoint in endometrial cancer, pivots to combo

 

Karyopharm to seek FDA accelerated approval for selinexor plus ruxolitinib in myelofibrosis

  • Company plans August FDA accelerated approval filing with priority review request for selinexor plus ruxolitinib regimen.
  • Phase 3 XPORT-EC-042 selinexor endometrial cancer trial missed primary PFS endpoint, leading to shift in R&D priorities.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)